Mechanisms of resistance to cancer immunotherapy
10.3760/cma.j.issn.0254-5101.2017.11.012
- VernacularTitle:肿瘤免疫治疗的耐药机制研究进展
- Author:
Tingting ZHANG
1
;
Linyu LI
;
Zheng SONG
;
Wei LI
;
Xiubao REN
;
Qiang PAN-HAMMARSTR?M
;
Kai FU
;
Xianhuo WANG
;
Huilai ZHANG
Author Information
1. 300060 天津医科大学肿瘤医院淋巴瘤科,中美淋巴血液诊治中心,国家肿瘤临床医学研究中心,天津市"肿瘤防治"重点实验室,天津市恶性肿瘤临床医学研究中心
- Keywords:
Immunotherapy;
Immune checkpoint;
Resistance mechanism
- From:
Chinese Journal of Microbiology and Immunology
2017;37(11):874-878
- CountryChina
- Language:Chinese
-
Abstract:
Cancer immunotherapy uses the host′s immune system to mobilize immune cells to rec-ognize and eventually eliminate cancer cells .At present, studies in terms of cancer immunotherapy mainly focus on programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) antibody, cytotoxic T-lymphocyte-associated protein 4 ( CTLA-4 ) antibody, chimeric antigen receptor T-cell immunotherapy (CAR-T), T cell receptor Immunotherapy (TCR-T), etc.Despite the fact that cancer immunotherapies elicit unprecedented durable responses in clinical therapy , they appear to be ineffective to some patients .In addition, some responders relapse and show resistance to immunotherapies even if their symptoms are re -lieved for a time .Resistance to cancer immunotherapy can be categorized into primary , adaptive and ac-quired, which can occur in every stage during the process of anti-tumor response.In this review, we discuss the known mechanisms of resistance and provide a rationale for the use of combination therapy to overcome resistance.
